Respira Therapeutics, Inc, a Samsara BioCapital portfolio company, today announced that it has entered into an agreement with Gossamer Bio, Inc. (Gossamer)(Nasdaq: GOSS) granting Gossamer an option to acquire the Company.

Respira Therapeutics, Inc.，作为Samsara BioCapital投资组合中的一家公司，今日宣布已与Gossamer Bio, Inc.（Gossamer）(纳斯达克股票代码：GOSS)达成协议，授予Gossamer收购该公司的选择权。

Respira is developing RT234 (vardenafil inhalation powder) as the first as-needed (PRN) therapy for use in pulmonary hypertension (PH). RT234 is designed to rapidly improve PH patient function and symptoms, including for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Respira公司正在开发RT234（伐地那非吸入粉剂）作为首个按需使用的（PRN）治疗肺动脉高压（PH）的疗法。RT234旨在快速改善PH患者的功能和症状，包括肺动脉高压（PAH）和与间质性肺病相关的肺动脉高压（PH-ILD）。

There are no approved PRN therapies for PAH or PH-ILD, and despite existing treatment options, the majority of PH patients continue to struggle with debilitating symptoms that disrupt daily life and limit their independence..

目前尚无获批的按需治疗肺动脉高压（PAH）或肺高压-间质性肺病（PH-ILD）的疗法，尽管已有现有的治疗选择，但大多数肺高压患者仍然面临影响日常生活的虚弱症状，限制了他们的独立性。

“We look forward to working closely with our colleagues at Gossamer, who share our

“我们期待与Gossamer的同事们紧密合作，他们与我们一样”

commitment to people living with PH, to expeditiously develop RT234 and making this unique therapy broadly available to patients,” stated John Kollins, Respira’s Chief Executive Officer. “We are excited to pair Respira’s technology and expertise with Gossamer’s established late- stage PH product development platform,” said Michael Dybbs, member of the Respira Board of Directors and partner at Samsara BioCapital.

“我们承诺为PH患者服务，迅速开发RT234，并使这种独特的疗法广泛惠及患者，”Respira首席执行官约翰·科林斯表示。“我们很高兴将Respira的技术和专业知识与Gossamer成熟的后期PH产品开发平台相结合，”Respira董事会成员、Samsara BioCapital合伙人迈克尔·戴布斯说道。

“We are confident that this transaction favorably positions RT234 to advance into late-stage clinical development.”.

“我们相信，这笔交易将使 RT234 有利地进入晚期临床开发。”

Pursuant to the option agreement, Gossamer is issuing 2.5 million shares of common stock in connection with the signing. Additionally, upon exercise of its acquisition option, Gossamer will issue an additional 1.5 million shares of common stock. In addition, the acquisition agreement provides for certain success-based clinical, regulatory, and commercial milestone payments and a royalty on potential net sales of RT234.

根据期权协议，Gossamer在签署协议时将发行250万股普通股。此外，在行使收购期权时，Gossamer还将额外发行150万股普通股。此外，收购协议还规定了某些基于成功的临床、监管和商业里程碑付款，以及RT234潜在净销售额的特许权使用费。

During the option period, which is anticipated to continue for up to approximately two years, Gossamer will fund and Respira will undertake certain pre‑agreed development activities focused on CMC work necessary to position RT234 for successful subsequent clinical development..

在预计将持续长达两年的期权期内，Gossamer 将提供资金，Respira 将开展某些预先商定的开发活动，重点放在 CMC 工作上，以确保 RT234 在后续临床开发中取得成功。

Respira is being advised by Sidley Austin LLP, Boston, Massachusetts.

Respira 得到了马萨诸塞州波士顿的盛德国际律师事务所的建议。

About Respira Therapeutics and RT234

关于Respira Therapeutics和RT234

Respira Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RT234 (vardenafil inhalation powder) as the first therapy that pulmonary hypertension patients can self-administer as-needed (PRN) to provide rapid, on-demand relief of exertional symptoms, such as breathlessness and reduced ability to perform basic daily activities, on top of chronic background therapies.

Respira Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发 RT234（伐地那非吸入粉）作为首个肺动脉高压患者可按需（PRN）自行给药的疗法，在慢性背景治疗的基础上，提供快速、按需缓解运动症状（如呼吸困难和执行基本日常活动能力下降）的功能。

These symptoms are widely prevalent among PH patients and often highly debilitating and disruptive to patients’ daily lives..

这些症状在肺动脉高压患者中广泛存在，常常严重削弱患者的日常功能并造成极大困扰。

RT234 incorporates novel and proprietary dry-powder formulation and inhaler technologies, including Respira’s Axial Oscillating Sphere Dry Powder Inhaler (AOS™-DPI), which maximize drug delivery to the deep lung. Vardenafil is a phosphodiesterase type 5 (PDE5) inhibitor approved in an oral dosage form for a non-PH indication.

RT234结合了新颖且专有的干粉配方和吸入器技术，包括Respira的轴向振荡球干粉吸入器（AOS™-DPI），这些技术能够最大化药物向肺深部的递送。伐地那非是一种磷酸二酯酶5型（PDE5）抑制剂，其口服剂型已被批准用于非PH适应症。

Although the PDE5 inhibitors sildenafil and tadalafil are FDA-approved in oral dosage forms for chronic treatment of PAH, on-demand administration of PDE5 inhibitors by inhalation in PH represents a novel treatment approach..

虽然PDE5抑制剂西地那非和他达拉非的口服剂型已获FDA批准用于PAH的慢性治疗，但通过吸入按需给药的PDE5抑制剂在肺动脉高压（PH）中代表了一种新的治疗方式。

Unlike existing PH treatments, RT234 is designed to provide rapid, on-demand relief of exertional symptoms and to be used on top of background therapies.

与现有的肺动脉高压（PH）治疗方法不同，RT234旨在提供快速、按需缓解运动症状，并在背景治疗的基础上使用。

In two completed open‑label Phase 2 studies in which a total of 56 PAH patients were treated with RT234, RT234 demonstrated rapid and clinically meaningful improvements in both hemodynamic and functional measures. Hemodynamic benefits included reductions in pulmonary vascular resistance and favorable changes in mean pulmonary arterial pressure and cardiac output.

在两项已完成的开放标签的 2 期研究中，共有 56 名肺动脉高压患者接受了 RT234 的治疗，RT234 在血液动力学和功能指标方面均表现出快速且具有临床意义的改善。血液动力学方面的益处包括肺血管阻力降低，平均肺动脉压和心输出量也有积极变化。

Acute functional improvements were also observed, including reduced breathlessness and increased exercise capacity during cardiopulmonary exercise testing. To date, RT234 has demonstrated a favorable safety and tolerability profile..

急性功能改善也很明显，包括在心肺运动测试期间呼吸困难减轻和运动能力增强。迄今为止，RT234 已表现出良好的安全性和耐受性。

About Gossamer Bio

关于Gossamer Bio

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension..

Gossamer Bio是一家处于后期阶段的临床生物制药公司，专注于开发和商业化用于治疗肺动脉高压和与间质性肺病相关的肺高压的Seralutinib。其目标是成为行业领导者，并改善肺高压患者的生活质量。

About Samsara BioCapital

关于Samsara BioCapital

Founded in 2017, Samsara BioCapital is a leading biotech investment firm focused on identifying opportunities across public and private markets. Samsara invests across the full spectrum from early-stage start-up to late-stage clinical assets with a focus on companies that will have a significant impact on patients and address high unmet medical needs.

Samsara BioCapital 成立于2017年，是一家领先的生物技术投资公司，专注于在公开和私人市场中寻找机会。Samsara的投资范围涵盖从早期初创企业到晚期临床资产的各个阶段，重点关注那些将对患者产生重大影响并满足高度未满足医疗需求的公司。

Samsara works with entrepreneurs and top-tier management teams that they believe will have a meaningful impact on innovative therapeutics. The Samsara team has deep expertise in biotech with significant experience working together prior to founding the firm. The team is led by Srinivas Akkaraju, who has over twenty-seven years of industry experience and has an MD and a PhD in.

Samsara与他们认为将对创新治疗产生重大影响的企业家和顶级管理团队合作。Samsara团队在生物技术领域拥有深厚的专业知识，在创立公司之前已有丰富的合作经验。团队由Srinivas Akkaraju领导，他在业界拥有二十七年以上的经验，并持有医学博士和哲学博士学位。

Immunology from Stanford University.

斯坦福大学的免疫学。

Contact:

联系人：

Respira Therapeutics, Inc. John Kollins

呼吸疗法公司，约翰·科林斯

Chief Executive Officer

首席执行官

ir@respiratherapeutics.com

ir@respiratherapeutics.com

Source: respiratherapeutics.com

来源：respiratherapeutics.com